Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, liraglutide, and exenatide, are an appealing option for the treatment of type 2 diabetes mellitus (T2DM) and obesity [22,23]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.